DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Idraparinux is an investigational drug.
There have been 5 clinical trials for Idraparinux. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2003.
The most common disease conditions in clinical trials are Venous Thrombosis, Thrombosis, and Pulmonary Embolism. The leading clinical trial sponsors are Sanofi and [disabled in preview].
Recent Clinical Trials for Idraparinux
|Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation||Sanofi||Phase 3|
|Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach||Sanofi||Phase 3|
|Bioequipotency Study of Idrabiotaparinux and Idraparinux in Patients With Deep Venous Thrombosis of the Lower Limbs||Sanofi||Phase 3|